Drawing for CARE|CONNECT SPECIALTY NETWORK

USPTO serial 87558105

CARE|CONNECT SPECIALTY NETWORK

Reviewed by CopyMark Law Group

Reg. 5457578Status 701Registered
Filing date
Status date
Registration date
May 1, 2018
Examiner
MARTIN, LIEF ANDREW
Law office
TMO LAW OFFICE 112

What this means

Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary. Calendar the 10-year Section 8 and 9 combined renewal.

Status 701: Status 701 means the registration is active and the first Section 8 declaration of continued use was accepted. The next major deadline is the combined Section 8 and Section 9 filing at the 10-year anniversary.

Need help with CARE|CONNECT SPECIALTY NETWORK?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Sheryl De Luca

Sheryl De Luca NIXON & VANDERHYE P.C.901 N. GLEBE ROAD, 11TH FLOORARLINGTON, VA 22203UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
035Health care utilization and review services as they relate to prescription drugs, namely, pharmaceutical cost management and drug utilization review services, verification of benefits, prior authorization and review services and coordination of delivery of and access to prescription drugs; Retail store and online retail pharmacy services featuring prescription drugs and healthcare products, namely, medical devices, over-the-counter medicine, health products, namely, vitamins, minerals, herbs, nutritional supplements, homeopathic remedies, personal care products, medical supplies for personal use; Retail pharmacy services featuring specialty pharmaceuticals; Specialized retail pharmacy services for patients with particular medical conditions using specialty medications; Specialized retail pharmacy services for patients with particular medical conditions, with a feature that enables patients to access co-pay assistance and other funding sources to pay for specialty medications; Retail pharmacy services rendered by telephone featuring prescription medications and specialty pharmaceuticals; Retail pharmacy services provided via a network of retail pharmacies; Pharmacy services, namely, retail pharmacy services, specialty retail pharmacy services, central fill retail pharmacy services and clinical retail pharmacy services; Specialty retail pharmacy services for patients with chronic illnesses; Specialty pharmacy services, namely, pharmaceutical distributorship services in the field of special purpose infusion-based, injectable and oral pharmaceuticals; Mail order services featuring specialty prescription drugs; Online ordering services featuring specialty prescription drugs; Specialty pharmaceuticals distributorship services; Business administration of pharmacy reimbursement programs for others; Pharmaceutical cost management services and drug utilization review services for patients with complex or chronic medical conditions; Business management and consultation services in the field of specialty pharmacy; Business management, advisory and consultation services for pharmacies regarding providing specialty pharmaceuticals to patients with serious medical conditions; Arranging of managed care contractual services in the fields of specialty pharmacy; Business administration of pharmacy reimbursement programs and services in the field of specialty pharmaceuticals for health benefit plan subscribers; Provision of specialty and non-specialty prescription medications and services ancillary thereto, namely, specialized retail pharmacy services for patients with particular medical conditions; Order fulfillment services, namely, monitoring and tracking the order status of prescription drugs, drug therapy, prescription refills; Managed care services, namely, electronic processing of health care information; Pharmaceutical cost management services and drug utilization review services for patients with complex or chronic medical conditions; Pharmaceutical services, namely, administering, processing, fulfilling, and tracking on-line prescription medication orders; Administering an order fulfillment program comprised of a network of medical services providers and pharmacies; Business management consultation, namely, assisting pharmacies in negotiating pricing and reimbursement levels, dispensing fees and other contractual terms with pharmacy benefit managers; Assisting pharmacies in negotiating pricing with pharmaceutical wholesalers; Providing an online database featuring customer order status informationACTIVEJul 22, 2015

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 12, 2024NAS8NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED—
Jan 12, 20248.OKREGISTERED - SEC. 8 (6-YR) ACCEPTEDThe USPTO accepted your Section 8 declaration showing the mark is still in use in commerce (or excusable nonuse). This satisfies the six-year maintenance requirement and keeps the registration active until the next renewal deadline.
Jan 12, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 30, 2023ES8RTEAS SECTION 8 RECEIVED—
May 1, 2023REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 1, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Feb 13, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 13, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 24, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 1, 2018ALIEASSIGNED TO LIE—
Dec 18, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 28, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 27, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 27, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 16, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 16, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 16, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 8, 2017DOCKASSIGNED TO EXAMINER—
Aug 11, 2017MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Aug 10, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 10, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance